New York, New York–(Newsfile Corp. – January 4, 2025) – A Leading Securities Law Firm Blishmar Fonte & Old LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) regarding potential violations of the federal securities laws.
If you have invested in BioAge, we encourage you to obtain additional information by visiting the website https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Why investigate BioAge?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The company's lead product candidate, Azelaprague, is an orally available small molecule agonist of the apelin receptor (APJ), designed to promote weight loss.
During the relevant period, the company reported that Azelaprague was well-tolerated in 265 individuals across eight Phase 1 clinical trials, and that following the company's IPO, it was “well-equipped to advance our clinical programs(.).”
Stocks decline as truth is revealed
On December 6, 2024, BioAge announced that it had discontinued the STRIDES phase 2 trial of azalaprage, due to safety concerns, after transaminase hepatitis was observed in people receiving azalaprage. The company stated that the decision to discontinue the STRIDES Phase 2 study of azelaprag “became clear” due to “the emerging safety profile of the current doses tested(.).”
This news caused the company's stock price to decline by more than 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.
Click here for more information: https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
What can you do?
If you invest in BioAge, you may have legal options and we advise you to provide your information to the company.
All representation is done on a contingency fee basis, at no cost to you. Shareholders bear no responsibility for any court costs or litigation expenses. The Company will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Why Blichmar Fonti & Old Co., Ltd.?
Bleichmar Fonti & Auld LLP is a leading international law firm that represents plaintiffs in securities class actions and shareholder lawsuits. It is ranked a Top 5 Law Firm for Plaintiffs by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA has recovered over $900 million in value from Tesla's (NASDAQ:) board (pending court approval), as well as $420 million from Teva Pharmaceuticals (NYSE:) Ind. . Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Lawyer advertisement. Past results do not guarantee future results.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235856
